Sotorasib, the Poster Child for Project Optimus: Truths and Fantasies
... 2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC. Ann Oncol. November 16, 2023 (early release online).
4. ...
... 2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC. Ann Oncol. November 16, 2023 (early release online).
4. ...
... in the United States
Sexual Health Assessment in Women With Lung Cancer Study: Sexual Health Assessment in Women With Lung Cancer
EGFR </em ...
... direct KRAS-G12C inhibition.
Figure 1. Resistance mechanisms to direct KRAS-G12C inhibition.
Table 1. Direct KRAS-G12C inhibitors. ...
... in the second-line setting in patients with KRAS G12C,” Ceullar said during the session. “[Adagrasib] also has a category 2A ...
Phase 3 PDL-1 > 50% Any KRAS mutation 30 vs. KRAS G12C 12 vs. No KRAS mutation 127 Any KRAS mutation 12 (HR = 0.51, 0.29–0.87;95% 95% CI ...
... the unmet needs of patients with KRAS -mutated NSCLC?
Porter : It is important to understand that many patients who have KRAS G12C ...
... mechanistic understanding of KRAS biology and the development of KRAS-mutant cancers. Relevant aspects range from KRAS-dependent ...
... a complete response letter denying full approval of Lumakras (sotorasib) for the treatment of adults with previously treated, locally ...
... number of observations looking at specific DNA alterations. In 2007, ALK fusions were described; in 2011, ROS1 fusions; shortly thereafter ...
... commonly diagnosed cancer worldwide, with 85% of those cases being NSCLC . Around 20% to 25% of NSCLC patients have a KRAS mutation</em ...